VaramirStart free · no cardSign in
MRNA as of Oct 31 · 08:15 ET
MRNANasdaqBiological Products, (No Diagnostic Substances)

Moderna, Inc. · Brief

Next report

5 days

Nov 5 · before openest.Q3 FY26
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
0 of 8≥ implied
avg implied
±8.2%
avg realized
±4.0%
Feb 14 '25±8.4%▲+3.35%×0.40
May 1 '25±9.1%▼−5.29%×0.58
Aug 1 '25±8.8%▼−6.61%×0.75
Nov 6 '25±7.5%▲+3.27%×0.44
Jan 12 '26±7.6%▼−1.34%×0.18
Feb 13 '26±7.7%▲+5.29%×0.69
Q1 FY26±6.9%▼−1.24%×0.18
Q2 FY26±9.8%▼−5.35%×0.55
quarterimplied−10%0+10%realized×
Q2 FY26±9.8%▼−5.35%×0.55
Q1 FY26±6.9%▼−1.24%×0.18
Feb '26±7.7%▲+5.29%×0.69
Jan '26±7.6%▼−1.34%×0.18
Nov '25±7.5%▲+3.27%×0.44
Aug '25±8.8%▼−6.61%×0.75
2 older reports
May '25±9.1%▼−5.29%×0.58
Feb '25±8.4%▲+3.35%×0.40
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 5 report · est.

Bull2 of 3

22.00%share of Personalis, Inc.'s revenue attributed to MRNA per their filingSEC filings
795managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 4

8 of 8recent reports where the move came in under options implied rangeEarnings history
1.41%of State Street SPDR S&P Biotech ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26
AI captions · Sep 16 '26once per report · top 2 per case

Linked exposure

MRNA report session

Customers 1

MRKMerck×0.08
× = co-movement · max 500dSource: SEC filings · market data

Latest changes

30 daysAll changes
Oct 22impliedImplied move: ±14.6% into Nov 5 earnings (Oct 22 close).Source
Oct 22haltTrading halt: 12:34 ET, resumed 12:39 ET.Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.